1928t2z car-t cell
Cell therapyexperimental
Clinical trial activity
4 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2019 (NCT04049513)
Timeline
Indications
Studied for
- Burkitt Lymphoma · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 2
- Lymphoma, Large-Cell, Immunoblastic · Phase 2
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 2
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06486051 | Phase 2 | Jul 12, 2024 | Malaghan Institute of Medical Research, Wellington Zhaotai Therapies Limited |
| NCT05757700 | Phase 1 | Feb 23, 2023 | Memorial Sloan-Kettering Cancer Center, Takeda |
| NCT04464200 | Phase 1 | Jul 6, 2020 | Memorial Sloan-Kettering Cancer Center, Takeda |
| NCT04049513 | Phase 1 | Aug 31, 2019 | Malaghan Institute of Medical Research, Wellington Zhaotai Therapies Limited |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Malaghan Institute of Medical Research | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Takeda | For profit | 2 | 0 | 1 | 2020 |
| Wellington Zhaotai Therapies Limited | For profit | 2 | 0 | 2 | 2019 |
4 organizations
Page 1 / 1